Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Moderate to Severe Plaque Psoriasis
NCT00723528Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2008
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Mar 2008; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT00723528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00723528.